These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 7249253)
81. Combination of immunotherapy with cyclophosphamide/actinomycin D chemotherapy potentiates antileukemic effect and reduces toxicity in a L1210 leukemia model in mice. Lasek W; Sora M; Wańkowicz A; Jakóbisiak M Cancer Lett; 1995 Feb; 89(1):137-43. PubMed ID: 7882296 [TBL] [Abstract][Full Text] [Related]
82. 2-(1-Oxyalkyl)-1,4-dioxy-9,10-anthraquinones: synthesis and evaluation of antitumor activity. Jin GZ; Song GY; Zheng XG; Kim Y; Sok DE; Ahn BZ Arch Pharm Res; 1998 Apr; 21(2):198-206. PubMed ID: 9875431 [TBL] [Abstract][Full Text] [Related]
83. Immunotherapy of L1210 leukemia using neuraminidase-modified plasma membranes combined with chemotherapy. Pincus JH; Jameson AK; Brandt AE Cancer Res; 1981 Aug; 41(8):3082-6. PubMed ID: 7248965 [TBL] [Abstract][Full Text] [Related]
84. Thiamine protection of murine L1210 leukemia cells against mechlorethamine cytotoxicity and its relation to the choline uptake system. Naujokaitis SA Res Commun Chem Pathol Pharmacol; 1981 May; 32(2):317-27. PubMed ID: 7244366 [TBL] [Abstract][Full Text] [Related]
85. Recent advances in sustained release of antineoplastic drugs using liposomes which avoid uptake into the reticuloendothelial system. Allen TM; Mehra T Proc West Pharmacol Soc; 1989; 32():111-4. PubMed ID: 2780575 [No Abstract] [Full Text] [Related]
86. Prolonged remissions of lymphatic leukemia in DBA-2 mice induced with endogenously produced lactate dehydrogenase antibody. Lakatos G; Strefling A; Joseph RR; McCann DS Cancer Res; 1974 Jun; 34(6):1395-400. PubMed ID: 4207862 [No Abstract] [Full Text] [Related]
87. Modified protocol for the testing of new synthetics in the L1210 lymphoid leukemia murine model in the DR&D program, DCT, NCI. Geran RI; Greenberg NH; Macdonald MM; Abbott BJ Natl Cancer Inst Monogr; 1977 Mar; (45):151-3. PubMed ID: 927490 [No Abstract] [Full Text] [Related]
88. Antitumor activity of benzamide riboside and its combination with cisplatin and staurosporine. Rauko P; Novotny L; Dovinova I; Hunakova L; Szekeres T; Jayaram HN Eur J Pharm Sci; 2001 Feb; 12(4):387-94. PubMed ID: 11231105 [TBL] [Abstract][Full Text] [Related]
89. Ultrastructural evidence of cardiac damage resulting from thoracic irradiation and anthracyclines in the rat. Kimler BF; Mansfield CM; Svoboda DJ; Cox GG Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1465-9. PubMed ID: 6469769 [TBL] [Abstract][Full Text] [Related]
90. Influence of pentagastrin administration on survival of mice with L1210 leukemia. Armata J; Srebo Z; Stankiewicz D; Wiliński B Cancer Treat Rep; 1983 Apr; 67(4):408. PubMed ID: 6850660 [No Abstract] [Full Text] [Related]
91. Relationship between the pharmacological activity of antitumor drugs Ametantrone and mitoxantrone (Novatrone) and their ability to condense nucleic acids. Kapuscinski J; Darzynkiewicz Z Proc Natl Acad Sci U S A; 1986 Sep; 83(17):6302-6. PubMed ID: 3462696 [TBL] [Abstract][Full Text] [Related]
92. Microwave treatment of intracerebral L1210 leukemia: schedule-dependent partial reversal of the effects of methotrexate. Chang BK; Huang AT; Joines WT Bioelectromagnetics; 1981; 2(1):77-80. PubMed ID: 7284044 [TBL] [Abstract][Full Text] [Related]
93. [Experimental studies of the combination of vincristine and 1,2:5,6-dianhydrogalactitol]. Fan YJ; Han R; Zhou J; Li M Yao Xue Xue Bao; 1987 Feb; 22(2):98-102. PubMed ID: 3618243 [No Abstract] [Full Text] [Related]
94. Hypothetical mechanism of therapeutic synergism induced by the combination of 6-thioguanine and 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride. Fujimoto S; Ogawa M; Sakurai Y Cancer Res; 1982 Oct; 42(10):4079-85. PubMed ID: 6955008 [No Abstract] [Full Text] [Related]
95. Synthesis and evaluation of the antitumor activity of 2-substituted 1,4-dihydroxy-9,10-anthraquinones. Tam MN; Nam NH; Jin GZ; Song GY; Ahn BZ Arch Pharm (Weinheim); 2000 Jun; 333(6):189-94. PubMed ID: 10909191 [TBL] [Abstract][Full Text] [Related]
96. Evaluation of antileukemic agents employing advanced leukemia L1210 in mice. VII. Venditti JM; Sheldon DR; Goldin A Cancer Res; 1964 Jan; 24(1 Pt 1):145-210. PubMed ID: 5878215 [No Abstract] [Full Text] [Related]
97. [Prevention and therapy of L1210 leukemia in mice, using inactivated and grafted tumor cells, in association with the immunomodulator P40, and Antineoplastic Agents (author's transl)]. Relyveld EH; Bizzini B; Ben-Efraim S C R Seances Acad Sci III; 1982 Mar; 294(12):571-6. PubMed ID: 6809234 [TBL] [Abstract][Full Text] [Related]
98. A new antitumor agent, (alphas, 4s, 5r)-alpha-amino-3-chloro-4-hydroxy-4,5-dihydro-5-isoxazoleacetic acid (NSC-176324): preliminary evaluation against L 1210 mouse leukemia in vivo. Martin DG; Hanka LJ; Neil GL Cancer Chemother Rep; 1974; 58(6):935-7. PubMed ID: 4217217 [No Abstract] [Full Text] [Related]
99. A proposal for the addition of hyperthermia to treatment regimens for acute and chronic leukemia. Robins HI; Dennis WH; Steeves RA; Sondel PM J Clin Oncol; 1984 Sep; 2(9):1050-6. PubMed ID: 6381656 [TBL] [Abstract][Full Text] [Related]
100. Experimental models and the role of RNA in immunotherapy of leukemia. Ono R; Esaki K; Kodera Y; Shiku H; Yamada K Ann N Y Acad Sci; 1973 May; 207():430-41. PubMed ID: 4517719 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]